Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diabetes Complications
Glucagon-like peptide 1 administration may reduce cardiovascular risk in type 2 diabetes
April 10th, 2006
Glucagon-like peptide 1 administration may reduce the cardiovascular risk in patients with type 2 diabetes. "Diabetic dyslipidaemia contributes to the excess morbidity and mortality in patients with type 2 diabetes. Exogenous glucagon-like peptide 1 (GLP-1) lowers postprandial glycemia predominantly by slowing gastric emptying," researchers in the United States report. "Therefore," proposed J.J. Meier and colleagues, University California Los Angeles, "the effects of GLP-1 on postprandial lipid levels and gastric emptying were assessed. 14 healthy male volunteers were studied with an i.v. infusion of GLP-1 (1.2 pmol*kg-1*min-1)...
Source: Diabetes Week (2006-04-10)
|
